The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…
The Pulmonary Fibrosis Foundation (PFF) is set to present the 13th edition of “Broadway Belts for PFF!” — an annual glitzy affair that has become the nonprofit’s single-largest fundraiser — on March 6. The gala, which also seeks to heighten awareness of pulmonary fibrosis (PF), will take place…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis in a mouse model of the disease, its developer, Kinarus Therapeutics, reported. When KIN001 was given with Esbriet, an approved treatment, the reduction in fibrosis was even greater than…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…
A protein called DACT2 alleviated signs of lung scarring in mouse models of idiopathic pulmonary fibrosis (IPF), researchers reported. In tests in cells, DACT2 was found to work by suppressing glycolysis, an energy-producing metabolic process that is overactive in myofibroblasts, the cells involved in excess scar tissue formation in IPF.
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules that would inhibit a protein called transglutaminase 2 (TG2), which plays a key role in fibrosis, or tissue scarring. Preclinical…
A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this year, according to the therapy’s developer, Algernon Pharmaceuticals. But plans for a Phase 2b study of NP-120 in people with idiopathic pulmonary fibrosis (IPF) are postponed “until…
Changes in blood levels of Krebs von den Lungen-6 — a protein produced by certain lung cells and known as KL-6 — can help predict the risk of disease progression in people with idiopathic pulmonary fibrosis (IPF) who’ve been treated with the anti-fibrotic medicines Esbriet (pirfenidone) and Ofev (nintedanib),…
Treatment with an extract of scorpion venom eased lung scarring in a mouse model of pulmonary fibrosis (PF), a study reported. The study, “Scorpion venom polypeptide governs alveolar macrophage M1/M2 polarization to alleviate pulmonary fibrosis,” was published in the journal Tissue and Cell. Scorpions and…
The Pulmonary Fibrosis Foundation (PFF) has added Cedars-Sinai Medical Center to its Care Center Network (CCN), a group of medical centers specializing in treating and supporting people with pulmonary fibrosis (PF). Cedars-Sinai is one of seven medical centers the foundation recently added to the network, bringing the total…
Get regular updates to your inbox.
